Abstract: Berzosertib, also known as VE-822, VX-970, or M6620, is a first-in-class, highly potent, and selective intravenously administered inhibitor of the Ataxia telangiectasia and Rad3-related (ATR) kinase. It has emerged as a promising targeted therapy for advanced solid tumors, exploiting the vulnerabilities of cancer cells with high replication stress or defective DNA damage response (DDR) pathways. By inhibiting ATR, berzosertib abrogates cell cycle checkpoints, forcing DNA-damaged cells into premature mitosis and subsequent apoptosis. Clinical and preclinical evaluations demonstrate its efficacy both as a monotherapy in tumors with ATM aberrations and in combination with DNA-damaging agents such as topotecan, gemcitabine, cisplatin, and radiotherapy. While challenges such as overlapping toxicities and the need for intravenous administration remain, ongoing research into novel dosing schedules, predictive biomarkers, and combination therapies continues to expand its therapeutic potential in precision oncology.
1. Introduction
Berzosertib (variously referred to in the literature as VE-822, VX-970, and M6620) is a first-in-class, intravenously administered inhibitor of the Ataxia telangiectasia and Rad3-related (ATR) kinase [1][2][3][4]. Developed by EMD Serono (Merck), it represents a significant advancement in precision oncology targeting the DNA damage response (DDR) network [2][4]. ATR is a critical component of the phosphoinositide 3-kinase-related protein kinase (PIKK) family, responsible for sensing DNA damage and replication stress [2]. Berzosertib is currently under extensive clinical evaluation for the treatment of multiple advanced solid tumors, both as a monotherapy and in combination with various chemotherapeutics and radiotherapy [1][4]. Its development is also pioneering global, Asia-inclusive clinical trial designs to ensure broad applicability across different ethnic populations [1].
2. Pharmacological Activity
Pharmacokinetics (PK): Berzosertib exhibits moderate to high clearance (approximately 60 L/h), a high volume of distribution (Vd; ~1250 L), and a terminal half-life (t1/2) of 17 hours [1]. Its pharmacokinetics are dose-linear across a range of 18 to 480 mg/m2 and remain unchanged upon the coadministration of combination drugs [1]. The drug is dosed on a body surface area-adjusted basis, which helps bridge demographic differences in body size. Population PK analyses have demonstrated no relevant ethnic differences in berzosertib exposure between Asian and non-Asian patients [1]. Furthermore, preclinical studies indicate that berzosertib possesses good blood-brain barrier (BBB) penetration, making it a viable candidate for treating brain metastases [2].
Clinical Efficacy: As a monotherapy, berzosertib is generally well tolerated at doses up to 480 mg/m2 with no dose-limiting toxicities (DLTs) [1]. It has shown durable single-agent antitumor activity in patients with advanced cancers harboring ATM aberrations, including a reported complete response in a colorectal cancer patient lasting over 20 months [3][4]. In combination therapies, berzosertib has demonstrated significant clinical benefit. When combined with topotecan, the recommended phase II dose (RP2D) yielded an objective response rate (ORR) of 36% in relapsed small cell lung cancer (SCLC), leading to durable regressions in chemotherapy-resistant small cell neuroendocrine cancers characterized by high replication stress [1][3]. In a phase II trial for platinum-resistant high-grade serous ovarian cancer, the combination of berzosertib and gemcitabine significantly prolonged progression-free survival (PFS) compared to gemcitabine alone (22.9 weeks vs. 14.7 weeks) [2][3]. It has also shown preliminary efficacy in combination with cisplatin in metastatic triple-negative breast cancer (TNBC) and is being evaluated alongside whole-brain irradiation for non-small cell lung cancer (NSCLC) brain metastases [2][4].
3. Molecular Mechanism of Action
Berzosertib functions by selectively inhibiting the ATR kinase, a master regulator of the DDR pathway [2][4]. ATR is activated by replication protein A (RPA)-coated single-stranded DNA (ssDNA) that arises at stalled replication forks or resected DNA double-strand breaks [4]. Upon activation, ATR phosphorylates downstream targets, most notably checkpoint kinase 1 (CHK1), which prevents genomic instability by stabilizing replication forks and inducing cell cycle arrest at the G2-M checkpoint to allow time for DNA repair [3][4].
By inhibiting ATR, berzosertib abrogates this critical cell cycle checkpoint. Clinical pharmacodynamic studies have shown that berzosertib reduces CHK1 phosphorylation by 73% to 90% in tumor biopsies [4]. This inhibition forces cancer cells with DNA damage or high endogenous replication stress to prematurely enter mitosis, leading to replication fork collapse, mitotic catastrophe, and cell death [3][4]. Berzosertib heavily relies on the concept of synthetic lethality. Because ATM and ATR exert overlapping functions in DNA repair, tumors with ATM deficiency (loss of protein expression or deleterious mutations) become overreliant on the ATR pathway, making them exquisitely sensitive to berzosertib monotherapy [3][4]. Additionally, tumors driven by oncogenes that induce high replication stress (e.g., MYC overexpression) are highly susceptible to ATR inhibition [3][4].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific chemical modifications and structure-activity relationship (SAR) mapping of the berzosertib molecule, it highlights the compound's potent biochemical profile. Berzosertib is a highly selective inhibitor of the ATR kinase within the PIKK family, demonstrating an IC50 of 19 nmol/L [2]. This high potency and selectivity are crucial for its ability to effectively modulate the DDR pathway without causing off-target inhibition of structurally related kinases such as ATM or DNA-PK, thereby maximizing its targeted synthetic lethal effects in cancer cells [2][3].
5. Current Limitations
Despite its clinical promise, the development and application of berzosertib face several limitations:
- Toxicity in Combination Therapies: While well-tolerated as a monotherapy, combining berzosertib with DNA-damaging chemotherapies (e.g., cisplatin, gemcitabine) can lead to overlapping and dose-limiting toxicities, particularly myelosuppression. Grade 3/4 adverse events such as neutropenia, anemia, and thrombocytopenia have been frequently observed in combination trials, necessitating careful dose adjustments [2][3][4].
- Route of Administration: Berzosertib is administered intravenously. Compared to newer, orally available ATR inhibitors (such as ceralasertib and elimusertib), intravenous administration is less convenient for patients and requires clinical infrastructure for infusions [3].
- Biomarker Identification: Selecting the optimal patient population remains a challenge. While ATM deficiency is a known predictor of response, confirming the loss or reduction of ATM in tumor samples is clinically difficult. Immunohistochemistry is not yet routinely applied, and scoring ATM mutations is complicated by the gene's large size and the presence of variants of unknown functional significance [3].
6. Future Perspectives
The future clinical development of berzosertib is focused on optimizing its therapeutic index and expanding its indications through rational combinations and biomarker-driven patient selection:
- Optimized Dosing Schedules: To mitigate toxicity to normal replicating cells, researchers are exploring "Gap-schedule" protocols. This involves administering berzosertib in the interval between doses of tumor-targeted DNA damaging agents (such as TOP1 inhibitors), allowing normal tissues to clear the chemotherapy while the tumor remains loaded with the drug [3].
- Novel Combinations: Berzosertib is currently being evaluated in combination with novel agents, including lurbinectedin, the antibody-drug conjugate sacituzumab govitecan, and PARP inhibitors [1][4]. Furthermore, preclinical evidence suggests ATR inhibitors can block PD-L1 upregulation, paving the way for trimodality therapies combining berzosertib, immune checkpoint inhibitors, and radiotherapy [4].
- Advanced Biomarkers: Beyond ATM mutations, future trials aim to utilize transcriptomic replication stress signatures and markers like Schlafen 11 (SLFN11) to better predict clinical responses to ATR inhibition [3].
- Global Drug Development: Leveraging ICH E5 and E17 guidelines, ongoing multiregional clinical trials (including safety run-ins in Japan and China) are ensuring that berzosertib's development is Asia-inclusive, facilitating seamless global access upon potential approval [1].
